<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462016000200149</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reacciones adversas a los fármacos antituberculosis en pacientes con esquemas mixtos]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse reactions to antituberculosis drugs in patients with mixed regimens]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Covarrubias-López]]></surname>
<given-names><![CDATA[Tania María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Laniado-Laborín]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Autónoma BC  ]]></institution>
<addr-line><![CDATA[Valle de las Palmas ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Baja California Hospital General Tijuana ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<volume>75</volume>
<numero>2</numero>
<fpage>149</fpage>
<lpage>154</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462016000200149&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462016000200149&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462016000200149&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Antecedentes:  La frecuencia real de los efectos adversos (EA) atribuibles al tratamiento de la tuberculosis resistente a los fármacos se desconoce debido a que con frecuencia no son notificados y, por ende, no se reportan.  Material y métodos:  Con el propósito de determinar la frecuencia de los EA en pacientes con tuberculosis sometidos a esquemas de tratamiento mixtos con fármacos de primera y segunda línea, se llevó a cabo una revisión de los archivos de la Clínica de Tuberculosis Resistente a Fármacos del Hospital General Tijuana.  Resultados:  Las reacciones adversas a los fármacos antituberculosis (RAFA) más frecuentes fueron la alteración de la función renal (75.9%), hepática (82.8%), hematológica (79.3%), digestiva (40%), auditiva (26.7%), vestibular (15%) y musculotendinosa (30%).  Conclusiones:  Los EA de los fármacos antituberculosis son muy frecuentes y constituyen un factor muy importante en la pérdida de adherencia al régimen. Deben ser monitoreados activamente y mitigados con tratamiento sintomático, cambios en los horarios de administración y, si el caso lo amerita, la suspensión del fármaco en cuestión.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Background:  The true frequency of adverse reactions (AR) attributed to antituberculosis drugs its unknown since they are seldom notified and therefore not reported.  Material and methods:  retrospective analysis of the files of the Tuberculosis Clinic at the Hospital General Tijuana to determine the frequency of AR in patients treated with a combination of first and second line antituberculosis drugs.  Results:  The most frequent AR to antituberculosis drugs were: renal dysfunction (75.9%), hepatitis (82.8%), hematologic abnormalities (79.3%), digestive AR (40%), hearing loss (26.7%), vestibular symptoms (15%) and tendinopathy (30%).  Conclusions:  AR to antituberculosis drugs are common and contribute to noncompliance. They must be routinely monitored and deal with, either with ancillary drugs, drug schedule modification and if needed with cessation of the offending drug.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[fármacos]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas]]></kwd>
<kwd lng="es"><![CDATA[toxicidad]]></kwd>
<kwd lng="en"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[drugs]]></kwd>
<kwd lng="en"><![CDATA[adverse reactions]]></kwd>
<kwd lng="en"><![CDATA[toxicity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Side effects associated with the treatment of multidrug-resistant tuberculosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Törün]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Güngör]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Özmen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2005</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1373-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbex]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Varella]]></surname>
<given-names><![CDATA[M de C]]></given-names>
</name>
<name>
<surname><![CDATA[Siqueira]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Mello]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Bras Pneumol]]></source>
<year>2010</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>626-40</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: Second-line drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbex]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Varella]]></surname>
<given-names><![CDATA[M de C]]></given-names>
</name>
<name>
<surname><![CDATA[Siqueira]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Mello]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Bras Pneumol]]></source>
<year>2010</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>641-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farazi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sofian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbariasl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Keshavarz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Tuberc Res Treat]]></source>
<year>2014</year>
<volume>2014</volume>
<page-range>412893</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saukkonen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Jasmer]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement hepatotoxicity of antituberculosis therapy]]></article-title>
<collab>ATS American Thoracic Society</collab>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2006</year>
<volume>174</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>935-52</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shean]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Streicher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pieterson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e63057</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Adverse effects and toxicity of antituberculosis drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laniado-Laborín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug resistant tuberculosis. Practical guide for clinical management]]></source>
<year>2015</year>
<page-range>74-84</page-range><publisher-name><![CDATA[Bentham e-books]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2011</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e21836</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Aminoglycosides nephrotoxicity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mingeot-Leclercq]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Tulkens]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>1999</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1003-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New developments in aminoglycoside therapy and ototoxicity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Talaska]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Schacht]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Hear Res]]></source>
<year>2011</year>
<volume>281</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>28-37</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fluoroquinolone-associated tendinopathy a critical review of the literature]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khaliq]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2003</year>
<volume>36</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1404-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<collab>Curry International Tuberculosis Center and California Department of Public Health</collab>
<article-title xml:lang=""><![CDATA[Adverse reactions]]></article-title>
<collab>California Public Health Department</collab>
<source><![CDATA[Drug-Resistant Tuberculosis: A Survival Guide for Clinicians]]></source>
<year>2016</year>
<edition>3</edition>
<page-range>146-71</page-range><publisher-loc><![CDATA[USA ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Efectos adversos y toxicidad de los fármacos antituberculosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laniado-Laborín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[El ABC de la tuberculosis resistente a los fármacos: Manual práctico de diagnóstico y tratamiento]]></source>
<year>2012</year>
<page-range>78-92</page-range><publisher-name><![CDATA[Editorial Académica Española]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
